9 Clinical manifestations and therapy of transfusional haemosiderosis

Bailliere's Clinical Haematology

Volumn 7, Issue 4, 1994, Pages 919-940

  Gabutti, V ^a   Borgna Pignatti, C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; IRON;

BLINDNESS; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; ENDOCRINE DISEASE; GROWTH INHIBITION; HEARING IMPAIRMENT; HEART DISEASE; HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON STORAGE; LIVER DISEASE; LUNG TOXICITY; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; ENDOCRINE DISEASES; FEMALE; HEART DISEASES; HEMOSIDEROSIS; HUMAN; IRON; LIVER DISEASES; MALE;

EID: 0028560319     PISSN: 09503536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3536(05)80131-3     Document Type: Article

References (108)

1. Nontransferrin-bound serum iron in thalassemia and sickle cell patients
2. Hearing loss and desferrioxamine in homozygous beta-thalassemia
3. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine
4. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation
5. Liver iron kinetic in thalassemic patients after bone marrow transplantation
6. Iron removal in ex-thalassemics after BMT: preliminary results from the phlebotomy program
7. Ocular changes in patients undergoing long-term desferrioxamine treatment
8. Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients
9. Long-term chelation in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress
10. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
11. Spleen iron content is low in thalassemia
12. The sicca syndrome in thalassaemia major
13. Visual loss in patients on high-dose subcutaneous desferrioxamine
14. Growth and sexual maturation in thalassemia major. A survey of 250 adolescents
15. Hepatocellular carcinoma in thalassaemia major
16. Outcome of thalassemia treated with conventional therapy
17. Magnetic-susceptibility measurement of human iron stores
18. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major
19. Effect of age at the start of iron chelation therapy on gondal function in β-thalassemia major
20. Iron in the heart: etiology and clinical significance
21. A short guide to the management of thalassemia
22. Internal distribution of excess iron and sources of serum ferritin in patients with thalassaemia
23. Biologic and clinical significance of red cell ferritin
24. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassemia
25. Hepatic iron overload: diagnosis and quantification by non-invasive imaging
26. Depletion of excessive liver iron stores with desferrioxamine
27. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy
28. Transfusion-related chronic liver disease in sickle cell anemia
29. Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees
30. Ocular toxicity of high-dose intravenous desferrioxamine
31. The development of diabetes mellitus in chronic liver disease in long term chelated beta thalassaemic patients
32. Insulin dependent diabetes in thalassaemia
33. Prevalence of endocrine complications in patients with β-thalassemia major: an Italian multicenter study
34. Chronic liver disease in transfusion-dependent thalassemia: liver iron quantitation and distribution
35. Deferoxamine-induced growth retardation in patients with thalassemia major
36. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia
37. Longitudinal study of cardiac function in thalassemia major
38. Prolonged survival in patients with betathalassemia major treated with deferoxamine
39. Subcutaneous desferrioxamine: the effect of three years treatment on liver iron, serum ferritin and comments for echocardiography
40. Treatment of Cooley's anemia
41. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions
42. Early left ventricular dysfunction and chelation therapy in thalassaemia major
43. Sustained normalization of cardiac function by chelation therapy in thalassaemia major
44. Current therapy for thalassemia in Italy
45. Toxicity of desferrioxamine treatment
46. Quality of life and life expectancy in thalassemic patients with complications
47. Long term results of standard management in thalassemia
48. Yersinia sepsis in patients with iron overload treated with deferoxamine
49. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy
50. Electroretinographic and visual evoked potential abnormalities in patients with beta thalassemia major
51. Deferoxamine improves left ventricular function in beta-thalassemia
52. Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis
53. Serum ferritin in diagnosis of haemochromatosis
54. Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity
55. Mechanism of iron chelation in the hyper transfused rat: definition of the two alternative pathways of iron mobilization
56. Results of long-term subcutaneous desferrioxamine therapy
57. Correlation between computed tomographic values and liver iron content in thalassemia major with iron overload
58. Serum immunoreactive trypsin in beta-thalassemia major
59. Acute changes in renal function associated with deferoxamine therapy
60. 40K
61. Desferrioxamine induced toxic retinal pigmentary degeneration and presumed optic neuropathy
62. Detection of early cardiac disfunction in patients with severe beta thalassaemia and chronic iron overload
63. Experimental hepatic cirrhosis in dogs caused chronic massive iron overload
64. Cardiac study by dobutamine stress echocardiography in thalassemic patients
65. Psychology of the thalassemia patient and his family
66. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion
67. Total management of thalassemia
68. Long-term desferrioxamine therapy in thalassemia
69. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis
70. Iron overload: clinical and pathologic aspects in pediatrics
71. Role of iron in ferritin and haemosiderin-mediated lipid peroxidation in liposomes
72. Visual and auditory neurotoxicity in patients receiving sub-cutaneous deferoxamine infusions
73. Computed tomography scanning of the liver to determine efficacy of iron chelation therapy in thalassemia major
74. Magnetic resonance imaging (MRI) of the iron loaded anterior pituitary gland in thalassemia major: correlation of signal intensity, T2 relaxation and hormonal status
75. Growth failure and bony changes induced by deferoxamine
76. Compliance with chelation therapy in Torino
77. Hearing loss and desferrioxamine
78. High dose desferrioxamine as a cause of growth failure in thalassemic patients
79. A new system for subcutaneous infusion of desferrioxamine
80. A new system for subcutaneous infusion of desferrioxamine
81. Deferoxamine chelation by intravenous implantable systems
82. Desferrioxamine-induced iron excretion in humans
83. Hepatocyte iron kinetics in the rat explored with an iron chelator
84. Liver iron stores before and after bone marrow transplantation for thalassemia
85. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
86. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major
87. Reassessment of the use of desferrioxamine B in iron overload
88. Yersiniae and iron. A study in host-parasite relationships
89. Depressed serum somatomedin activity in beta-thalassemia
90. The 13th Meeting of the European Society for Paediatric Haematology and Immunology (ESPHI)
91. Hepatic pathology in relatives of patients with haemochromatosis
92. Hepatocellular transferrin receptor expression in secondary siderosis
93. A direct method for quantification of nontransferrin bound iron (NTBI)
94. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy
95. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major
96. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
97. Family reactions and relationships in thalassemia
98. Hepatocellular uptake of ferritin in the rat
99. Erythrocyte ferritin content in idiopathic haemochromatosis and alcoholic liver disease with iron overload
100. Compliance with therapy in Cooley's anaemia
101. Relationship of hepatic iron concentration to histochemical grading and to total chelatable body iron in conditions associated with iron overload
102. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias
103. The effect of long survival on the pathology of thalassaemia major
104. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
105. Cardiac complications in homozygous beta-thalassemia
106. Binding of serum ferritin to concanavalin A: patients with homozygous β-thalassaemia and transfusional iron overload
107. Survival and causes of death in thalassemia